<DOC>
	<DOCNO>NCT02802605</DOCNO>
	<brief_summary>Prospectively evaluation incidence thromboembolic event hospitalize cirrhotic patient . 2 . Efficacy safety use bemiparin prevent peripheral portal thrombosis . 3 . Monitoring antiXa level .</brief_summary>
	<brief_title>Safety Efficacy Bemiparin Prevention Thrombotic Events Hospitalized Cirrhotic Patients</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : To evaluate safety prophylactic anticoagulation Bemiparina ( HIBOR® ) prevention peripheral portal vein thrombosis cirrhotic patient prolonged hospitalization . Secondary objective follow : 1 . To evaluate incidence thrombotic event hospitalize cirrhotic patient . 2 . To evaluate efficacy low molecular weight heparin ( HIBOR 3.500UI ) prevent thrombotic event hospitalize cirrhotic patient . 3 . To identify risk factor development portal vein thrombosis deep vein thrombosis hospitalize patient . 4 . Evaluate morbidity mortality associate thromboembolic event . 5 . Evaluate prophylactic anticoagulation level determine antiXa antithrombin III . 6 . To study expression profile functionality Toll-like receptor factor intimately involved inflammatory response , well variability different serum marker associate proinflammatory state : I-FABP / IL6-IL8 / NO , endothelin LPS-binding protein . 7 . Evaluate effect liver fibrosis ( Fibroscan® ) serum TGF 8 . Evolution hepatocellular function estimate score Child-Pugh MELD .</detailed_description>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Liver cirrhosis etiology diagnose previous biopsy clinical , laboratory sonographic criterion 2 . Hospital admission least 3 day , decompensated liver disease ( ascites , encephalopathy , control gastrointestinal bleeding , spontaneous bacterial peritonitis ) 3. sign write consent 4 . Women childbearing age use effective contraception 1 . Age &lt; 18 &gt; 80 year 2. contraindication treatment heparins 3. uncontrolled hemorrhage 4 . Any comorbidity involve therapeutic limitation / life expectancy &lt; 6 month 5. concomitant antiplatelet therapy ( aspirin , clopidogrel , ticlopidine , dipyridamole , sulfinpyrazone , dextran 40 , anticoagulant 6. continue concomitant NSAIDs , salicylates , corticosteroid 7. existence clinically significant esophageal varix / severe gastropathy portal hypertension without previously treat primary / secondary prophylaxis ( endoscopic variceal ligation / non cardioselective beta blocker ) 8 . Refusal participate study , sing informed consent 9 . Pregnancy lactation 10 . HIV infection 11. platelet count &lt; 20,000 platelet / dl 12. renal clearance 30ml / min 13. portal vein thrombosis peripheral thrombosis diagnose admission 14. presence procoagulant factor previously know</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>